To account for these vascular alterations, we examined expression of two key groups of angiogenic factors involved in GBM neo-vascularization: Vascular endothelial growth factor A (VEGFA) and angiopoietin 2 (ANG2)/angiopoietin 1 (ANG1), in response to a decrease in HK2. The gene discussed is ANGPT1; the disease is glioblastoma.